Rate My Professor David Erritzoe

Dr. David Erritzoe, MD, PhD, MRCPsych, is a psychiatrist and neuroscientist holding the position of Clinical Associate Professor in Psychopharmacology and Psychiatry within the Department of Brain Sciences, Faculty of Medicine at Imperial College London. He serves as Clinical Director of the Centre for Psychedelic Research and the CNWL-Imperial Psychopharmacology and Psychedelic Research Clinic (CIPPRes). Erritzoe received his medical training and PhD from University Hospital Rigshospitalet in Copenhagen, Denmark, where he also conducted postdoctoral work at the Neurobiological Research Unit and Center for Integrated Molecular Brain Imaging (CIMBI). He trained in PET neuroimaging at Columbia University in New York before joining Imperial College London in 2004 as a Research Psychiatrist in the Centre for Psychiatry, Neuropsychopharmacology Unit, Division of Brain Sciences. He advanced through positions including Lecturer at the Centre for Neuropsychopharmacology and NIHR Academic Clinical Lecturer, becoming a post-CCT consultant psychiatrist.

Erritzoe's research focuses on the neurobiology and therapeutic applications of psychedelics, utilizing advanced neuroimaging techniques such as PET and fMRI to explore serotonin systems, neuroplasticity, and treatment mechanisms for major depressive disorder, addiction, schizophrenia, and personality disorders. He has authored over 150 scientific papers, contributed to seven books including six chapters, and garnered more than 19,000 citations with a Scopus h-index of 54 as of December 2025. Notable publications include 'Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study' (2016, The Lancet Psychiatry), 'Effects of psilocybin therapy on personality structure' (2018, Acta Psychiatrica Scandinavica), 'Trial of psilocybin versus escitalopram for depression' (2021, New England Journal of Medicine), and 'A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial' (2026, Nature Medicine). His contributions have advanced clinical trials integrating psychedelics into NHS settings and influenced the field through editorial roles and public lectures at forums like the British Association for Psychopharmacology. Erritzoe received Imperial College's President's Award for Excellence in Research in 2025 and recognition as a Clarivate highly cited researcher in the top 0.1% globally that year.